Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis - 16/08/18
Abstract |
Background |
Atopic dermatitis (AD) has been associated with anxiety and depression, but the magnitude of the alleged association is unknown.
Objective |
To perform a systematic review and meta-analysis of the association between AD in children and adults and, respectively, depression, anxiety, and suicidal behavior.
Methods |
The medical databases PubMed, Embase, and PsychINFO were searched.
Results |
There was a significant association between adult AD and, respectively, depression (pooled odds ratio [OR], 2.19; 95% confidence interval [CI], 1.87-2.57) and anxiety (pooled OR, 2.19; 95% CI, 1.75-2.73). AD was also associated with depression in children (pooled OR, 1.27; 95% CI, 1.12-1.45); few data were available for anxiety. A positive association was found between AD in adults and adolescents and suicidal ideation (pooled OR, 4.32; 95% CI, 1.93-9.66). Only a few studies examined the risk of completed suicide, but the majority showed a positive association between completed suicide and AD.
Limitations |
Included studies used different definitions of depression and anxiety, and few studies examined the severity of AD.
Conclusion |
Depression, anxiety, and suicidal ideation should be considered by doctors when treating patients with AD. Because AD disease improvement appears to reduce these risks, this should be a priority.
Le texte complet de cet article est disponible en PDF.Key words : anxiety, atopic dermatitis, depression, meta-analysis, suicidal ideation, suicide, systematic review
Abbreviations used : AD, CI, NOS, OR
Plan
Ms Rønnstad and Ms Halling-Overgaard contributed equally to this project. |
|
Funding sources: Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation. Ms Anne-Sofie Halling-Overgaard is supported by a scholarship from Herlev and Gentofte Hospital. |
|
Disclosure: Dr Thyssen has attended an advisory board for Roche and Sanofi-Genzyme and been a speaker on atopic dermatitis for LEO Pharma and Sanofi-Genzyme. Dr Skov has received research funding from Sanofi, LEO Pharma, Pfizer, Novatis, and Janssen, as well as honoraria as a consultant and/or speaker from Pfizer, AbbVie, Eli Lilly, Novartis, LEO Pharma, Janssen-Cilag, and Sanofi; Dr Skov has also served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, Boehringer Ingelheim, and LEO Pharma. Dr Egeberg has received research funding from Pfizer and Eli Lilly and honoraria as a consultant and/or speaker from LEO Pharma, Samsung Bioepis, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Ms Halling-Overgaard, Ms Rønnstad, and Dr Hamann have no conflicts of interest to disclose. |
|
Dr Thyssen, Dr Egeberg, Ms Halling-Overgaard, and Ms Rønnstad had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis, as well as for the study concept and design. All the authors take responsibility for acquisition, analysis, and interpretation of the data; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; and study supervision. Dr Thyssen, Dr Hamann, Ms Halling-Overgaard, and Ms Rønnstad take responsibility for drafting of the manuscript. Dr Egeberg takes responsibility for statistical analysis. |
|
Reprints not available from the authors. |
Vol 79 - N° 3
P. 448 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?